Puma Biotechnology (PBYI) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Puma Biotechnology (PBYI) do?
Puma Biotechnology Inc (PBYI) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells neratinib tablets under the brand name Nerlynx to treat HER2-positive early and metastatic breast cancer. It is worth $368.09M on the market and sold $231.50M over the last year.
- Market cap
- $368.09M
- P/E ratio
- 15.7×
- Annual sales
- $231.50M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 12, 2026
Brands and businesses behind PBYI
- Nerlynx: A daily prescription tablet that earns revenue through treatment of HER2-positive breast cancer.
PBYI’s flags, in plain English
Each flag is a number from Puma Biotechnology’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.
Low debt
Low debt, only 3% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 73.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Cheap on Cash Flow
Priced at 8 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Growth Cooling
Sales growth slowed to 0.3% a year over 5 years. Sales are growing more slowly than before, which makes the current share price harder to justify.
2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about PBYI
How big is Puma Biotechnology?
Puma Biotechnology’s market cap is $368.09M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $231.50M: what customers paid the company over the last year, before any costs.
What is PBYI’s P/E ratio?
PBYI’s P/E ratio is 15.7×. Investors pay about 15.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with PBYI?
Revenue depends almost entirely on sales of a single commercial medicine. That is one risk on Puma Biotechnology’s card. Its first risk flag is Growth Cooling, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Puma Biotechnology’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PBYI’s filings on SEC.gov. The Margin Monkey is research, not advice.
